Year-end filings for Novartis' LAMA glycopyrronium bromide in COPD
This article was originally published in Scrip
Executive Summary
Novartis has announced plans to file for regulatory approval of its inhaled long acting muscarinic receptor antagonist, NVA237 (glycopyrronium bromide), for chronic obstructive pulmonary disease (COPD) before the end of 2011, saying that submissions will include new data from a second pivotal Phase III trial of the drug, GLOW2.